AstronauTx Raises $61M in Series A Financing for New Alzheimer’s Treatments
Supporters include Novartis Venture Fund, Brandon Capital, and more.
AstronauTx announced in a company press release that it has raised $61 million as a result of Series A funding. With funding led by the Novartis Venture Fund, several others contributed including Brandon Capital, Bristol Myers Squibb, EQT Life Sciences investing from the LSP Dementia Fund, MPM Capital with participation from current investor, the Dementia Discovery Fund. The company intends to use the proceeds to develop new treatments for Alzheimer’s disease.
"We now know that the processes causing Alzheimer's and other similar diseases are modifiable.Progress towards a compendium of new drugs against these devastating diseases is thankfully well underway. Our treatments will be oral drugs, applicable across multiple neurodegenerative conditions, and additive with mechanisms that are currently in late-stage development," said Ruth McKernan, PhD, CBE, co-founder, AstronauTx.
Reference: AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer's disease. PR Newswire. October 9, 2023. Accessed October 9, 2023. https://www.prnewswire.com/news-releases/astronautx-closes-48-million-61-million-series-a-financing-to-create-new-treatments-for-alzheimers-disease-301949897.html
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
